30.96
+0.36%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Junshi Biosciences Co
Its shares trade on Shanghai under the ticker 688180.SS. It has been listed since 15 July 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.43bn and a net loss of CN¥851.8m. At that date it held total assets of CN¥12.39bn and shareholders' equity of CN¥6.03bn.
Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-07-15. Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The firm develops innovative drugs and provides clinical research commercialization services worldwide. The firm mainly provides its products in the treatment of tumor immunotherapy, metabolic diseases, inflammation or autoimmune diseases, as well as nervous system diseases. The firm's products are mainly used to treat melanoma, nasopharyngeal cancer, esophageal cancer, urothelial cancer, malignant lymphoma and others. The firm provides its products for domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Jul 2020
- Employees
- 600
- Website
- junshipharma.com ↗
Leadership
Pay as last reported
- Mr. Jun XiongExecutive Chairman of the Board, since 2015CN¥3.8m
- Ms. Jianjun ZouChief Executive Officer, General Manager, Executive Director, since 2022CN¥9.0m
- Mr. Cong LiCo-Chief Executive Officer, Executive Director, since 2016CN¥4.1m
- Mr. Ning LiExecutive Vice Chairman of the Board, since 2018CN¥6.4m
- Mr. Baohong XuChief Financial OfficerCN¥2.1m
- Mr. Gang WangDeputy General Manager, Executive Director, Chief Quality Officer, since 2019CN¥4.2m
- Mr. Sheng YaoDeputy General Manager, Executive Director, since 2015CN¥3.8m
- Mr. Zhuobing ZhangDeputy General Manager, Executive Director, since 2016CN¥5.3m
- Ms. Xin LiExecutive Director, Senior Vice President - Government Affairs Unit, since 2023CN¥462,700
- Mr. Zhengyu WangSecretary of the BoardCN¥476,000
- Mr. Yi TangNon-Executive Director
- Mr. Zhongxian LiIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 97
- Social
- 75
- Governance
- 47
- Direct emissions (scope 1)
- 5,307.75 t
- Energy emissions (scope 2)
- 21,493 t
- Women in the workforce
- 52.36618%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Reputation: Shanghai Junshi Biosciences Co Ltd has established a strong reputation in the biotechnology industry, known for its innovative research and development in the field of biosciences.
- Robust Pipeline: The company possesses a robust pipeline of potential drug candidates, indicating future growth potential and opportunities for commercialization.
- Strategic Partnerships: Junshi Biosciences has formed strategic partnerships with leading pharmaceutical companies, enabling access to resources, expertise, and collaborative opportunities.
Weaknesses
- Dependency on Limited Products: Although Junshi Biosciences has a strong pipeline, its current revenue heavily relies on a limited number of products. Any setbacks or failures in these products could have a significant impact on the company.
- Relatively New Player: Compared to some of its competitors, Junshi Biosciences is relatively new in the industry. This may pose challenges in terms of market penetration, brand recognition, and trust among potential partners and investors.
Opportunities
- Growing Demand for Innovative Medicines: The global market for innovative medicines is expanding rapidly, providing an opportunity for Junshi Biosciences to further develop and commercialize its drug candidates.
- Emerging Markets: Junshi Biosciences can explore and expand into emerging markets, where there is a rising demand for healthcare products and potential partnerships.
Threats
- Intense Competition: The biotechnology industry is highly competitive, with numerous players vying to develop breakthrough drugs. Junshi Biosciences faces the risk of competition from both established and emerging biotech/pharmaceutical companies.
- Regulatory Challenges: The regulatory environment for the biotech industry can be complex and stringent, requiring extensive testing, clinical trials, and regulatory approvals. Delays or failures in obtaining necessary approvals can hinder the company's progress.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.